Lara Longpre

2022

In 2022, Lara Longpre earned a total compensation of $1.5M as Chief Development Officer at Mirum Pharmaceuticals.

Compensation breakdown

Non-Equity Incentive Plan$216,000
Option Awards$670,596
Salary$450,000
Stock Awards$158,700
Other$12,200
Total$1,507,496

Longpre received $670.6K in option awards, accounting for 44% of the total pay in 2022.

Longpre also received $216K in non-equity incentive plan, $450K in salary, $158.7K in stock awards and $12.2K in other compensation.

Rankings

In 2022, Lara Longpre's compensation ranked 2,205th out of 5,625 executives tracked by ExecPay. In other words, Longpre earned more than 60.8% of executives.

ClassificationRankingPercentile
All
2,205
out of 5,625
61st
Division
Manufacturing
1,190
out of 3,053
61st
Major group
Chemicals And Allied Products
517
out of 1,380
63rd
Industry group
Drugs
475
out of 1,281
63rd
Industry
Pharmaceutical Preparations
343
out of 927
63rd
Source: SEC filing on May 1, 2023.

Longpre's colleagues

We found three more compensation records of executives who worked with Lara Longpre at Mirum Pharmaceuticals in 2022.

2022

Christopher Peetz

Mirum Pharmaceuticals

Chief Executive Officer

2022

Peter Radovich

Mirum Pharmaceuticals

Chief Operating Officer

2022

Pamela Vig

Mirum Pharmaceuticals

Head of Research and Development

News

You may also like